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Abstract 
 
Thin sections of pleura and lung prepared for diagnosis of Malignant Mesothelioma (MM) in patients who 
underwent pleurodesis were analysed by micro-Raman spectroscopy. In the pleural tissue, visual 
inspection under an optical microscope attached to the Raman spectroscope revealed numerous acicular 
crystals and several rounded particles, micrometers in size. The laser beam of the spectrometer was 
focused on each of the inorganic phases in turn, revealing Raman spectra attributable to talc or to 
clinochlore on the acicular crystals and to phosphate phases on the rounded particles. In the lung tissue, 
optical inspection indicated the presence of asbestos bodies, identified by micro-Raman spectroscopy as 
crocidolite, “asbestos” mineral, the phase of the fibre inside the coating material. The identity of the 
inorganic phases as determined by Raman spectroscopy was confirmed by chemical analysis using a 
Scanning Electron Microscope equipped with an Energy Dispersive Spectrometer (SEM/EDS). Micro-
Raman spectroscopy proved effective in identifying the inorganic phases present in thin sections 
prepared for medical diagnosis, allowing compounds introduced during treatment (talc or clinochlore) to 
be distinguished from those inhaled (asbestos) or crystallized during disease progression (phosphates). 
 
1. Introduction 
 
Malignant Mesothelioma (MM) is an aggressive form of pulmonary cancer strongly associated with 
asbestos exposure [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13] and [14]. Its diagnosis can be 
suspected from analysis of pleural liquid or a fragment of neoplasia by trans-chest biopsy but can only be 
definitely confirmed by surgical specimen or post-mortem analysis. Identifying biological markers for 
asbestos exposure is thus of great interest in resolving the complex medico-legal problems, often 
associated with the disease. A number of biological markers are under investigation, including pleural 
plaques revealed by radiological tests and observations made by Optical Microscopy (OM) and/or 
Electron Microscopy (EM) of cytological/histological sections taken during surgical treatment of 
uncovered and/or covered asbestos fibres (“asbestos bodies”). In recent years, our research group has 
been using micro-Raman spectroscopy to identify the mineral phases in histological sections from 
patients affected by important respiratory diseases, without digestion of the organic matrix [15] and [16]. 
This technique could help the investigations, and we would confirm it as reliable also when 
mesothelioma is treated with talc injection during pleurodesis, a commonly used palliative procedure in 
MM for the prevention of recurrent fluid accumulation. Pleurodesis consists of the introduction of a 
sclerosing agent to achieve the symphysis of visceral and parietal pleura. Talc is recognized by the 
American Thoracic Society and European Respiratory Society Task Force for the management of 
malignant pleural effusion as the best sclerosing agent, although talc itself can be involved in pulmonary 
diseases. In fact, pleural tissue responds to talc by developing a foreign body granuloma, often appearing 
as foreign body giant cells, containing crystalline materials. The term talco-silicosis or talco-asbestosis is 
sometimes applied to the resulting pneumoconiosis, especially when the talc is contaminated by silica or 
by asbestos phases. Deposits of ferruginous bodies, very similar to those induced by asbestos, have also 
been described [17], [18], [19], [20], [21], [22], [23] and [24]. In these cases, histological evaluation does 
not appear adequate to differentiate talc pneumoconiosis from asbestosis. Moreover, talc can penetrate 
the lung through the lymphatic vessels and may lead to the formation of a peri-bronchiolar granuloma or 
fibrosis resembling other pneumoconioses induced by asbestos minerals. Raman spectroscopy thus 
proves an useful tool, making it possible to analyze thin sections made for medical diagnosis of the 
disease to accurately distinguish inhaled fibres from inorganic phases introduced during treatment. In 
this study, direct micro-Raman spectroscopy of the inorganic phases observed in histological pleural-lung 
sections was coupled with chemical analysis performed by SEM/EDS (Scanning Electron Microscopy with 
Energy Dispersive Spectroscopy). 
2. Experimental 
 
To determine the characteristics of the powder used for pleurodesis (Talc de Luzenac, STERILTALC® F4, 
NOVATECH), its mineral composition was analyzed by the X-ray powder method using an X’TRA Thermo 
ARL Diffractometer working in θ:θ geometry, Cu (Kα) radiation and equipped with a “Peltier” detector. 
The spectra were recorded at a scan rate of 0.2°/min in a 2θ range 2-70° to detect mineral phases 
present even in very small amounts. The data were processed using the WinXRD software, version 2.0-5. 
 
Pleura and/or lung samples from six patients, affected by MM, were first embedded in a paraffin block, 
and then sliced with a microtome into 3 μm thick sections. The sections were mounted and fixed on 
slides and then placed in an oven at 60° C, the melting point of the paraffin. In a departure from routine 
procedure, the sections were not stained with Haematoxylin & Eosin, to avoid the risk that their Raman 
bands might overlap with those of the inorganic particles/fibres under analysis. The sections were first 
observed under an OM equipped with two polarizers to identify the inorganic phases by means of their 
optical properties under crossed nicols. The crystals optically detected were analysed under micro-
Raman spectroscopy using a Jobin Yvon HR800 LabRam μ-spectrometer equipped with an Olympus BX41 
microscope, a HeNe 20 mW laser working at 632.8 nm and a CCD (charge-coupled device) air-cooled 
detector. The instrument was carefully calibrated by checking position and intensity of the Si band at ± 
520.6 cm−1 before every run. To increase the signal to noise ratio, 50 repeats of 10 second integration 
time spectra were carried out. The spectra registered were processed using the ORIGIN software, version 
6.0. The Raman region of interest was 1200-200 cm−1, containing the vibrational lattice modes identified 
by Rinaudo et al. [25] and [26] and useful for distinguishing the different asbestos minerals. Raman bands 
with an asymmetric appearance were processed with the curve-fitting tool of the OPUS software, version 
4.0. Band fitting was carried out using a Gaussian function introducing the minimum number of 
component bands in the process. Fitting was performed until reproducible results were obtained with 
the minimum residual error. 
 
After being characterized by micro-Raman spectroscopy, each particle/fibre was studied under VP-
SEM/EDS, Variable Pressure SEM/EDS, model E-SEM Quanta 200, FEI company, equipped with an EDS 
microprobe, EDAX, for microanalysis. This instrument allows samples to be characterized without being 
coated first, so the inorganic phases can be identified directly in the biological matrix in which they are 
incorporated. The value of pressure used was 90 Pa, under 20 kV accelerating voltage; the spectra 
registered were processed using the GENESIS software, version 3.6. The inorganic particles/fibres were 
very small and thin, so to determine the contribution of the cellular composition to the chemical values 
obtained under EDS, analyses were always performed either on the inorganic particle/fibre (IN) or in 
areas external (OUT), close to it. The difference was then calculated between the average IN values and 
the average OUT values in order to obtain a qualitative analysis of the inorganic phase being examined. 
 
After carbon coating of the thin section, quantitative chemical analysis of the phosphate particles was 
also carried out under a SEM Cambridge Stereoscan S360 equipped with an EDS, Oxford INCA Energy 200 
coupled with a SATW PentaFET detector. The accelerating voltage was 15 kV. Quantitative data were 
calculated by means of the INCA Microanalysis Suite software package, version 4.08, using the reference 
standards of albite for Na, periclase for Mg, apatite for P and wollastonite for Ca. 
3. Results 
 
The X-ray spectrum of the powder used for pleurodesis is shown in Fig. 1. As expected, talc appears as 
the predominant phase; in fact, almost all of the peaks detected may be ascribed to the same mineral: 
phyllosilicate, with the chemical composition Mg6[Si8O20](OH)4[27]. Nevertheless, other peaks (CHL in 
Fig. 1), which were weak in intensity, on the spectrum and not ascribable to talc were also observed. 
These can be assigned to clinochlore, a mineral phase with the chemical composition 
[(Mg10Al2)(Si6Al2O20)(OH)16], in which substitutions of Fe for Mg may occur [27]. This mineral, too, is a 
phyllosilicate, but it belongs to the family of clay minerals. This last phase is therefore an impurity in the 
powder used for talc-pleurodesis. 
    Fig. 1.  
 
    X-ray powder pattern of the powder used for pleurodesis. All the observed peaks, except for the peaks 
indicated as CHL, are ascribed to Talc; CHL peaks are ascribing to clinochlore, present as an impurity in 
the powder (Talc de Luzenac, STERILTALC® F4, NOVATECH). 
 When analysed under the OM, thin sections from the patients affected by MM and undergone 
pleurodesis show a parietal and visceral pleura characterized by a fibrosclerotic process, a residual area 
of mesothelioma and a band of granulomatous reaction with strong birefringent crystals, Fig. 2, onto 
which the laser of the spectroscope was focussed. Two types of spectra were registered: 
 
a) 
 
    in the majority of cases and on the thinner crystals, as shown in Fig. 3a, the spectrum shown in Fig. 3b 
was obtained: the wavenumbers of the Raman bands and their relative intensities identify the phase as 
talc [16]; 
Fig. 3.  
 
(a) An elongated crystal analysed by micro-Raman spectroscopy. (b) Raman spectrum registered on the 
crystal shown in Fig. 3a and obtained on a great number of the elongated crystals examined. The 
wavenumbers of the Raman bands and their relative intensity indicate talc. Circled bands are produced 
by the paraffin film covering the thin section. 
 
b) 
 
    sometimes, on thicker crystals, Fig. 4a, the spectrum reported in Fig. 4b was registered; the 
wavenumbers of the Raman bands allow this phase to be ascribed to “clinochlore”. 
Fig. 4.  
 
(a) More thick crystal on which the Raman spectrum indicating chlinoclore was registered. (b) Raman 
spectrum sometimes registered and corresponding to clinochlore. Circled bands are produced by the 
paraffin film covering the thin section. 
    Fig. 2.  
 
    Optical photograph of pleural section: on the left, neoplastic mesothelial proliferation; on the right, a 
granulomatous reaction to the powder used for pleurodesis. In this case, the histological section has 
been treated with haematoxylin and eosin to better highlight the cellular medium around the inorganic 
phases. 
 
It must be emphasized that, in Fig. 3b and 4b, all the bands characterizing the Raman spectra from the 
natural samples of talc [15] and of clinochlore can be seen [28] and [29]. We read this spectroscopic 
behaviour as an indication of a three-dimensional crystal structure of the injected mineral phases that is 
not strongly affected by interaction with the cellular medium. As for the chemical composition of the 
crystals studied under micro-Raman spectroscopy, as expected, VP-SEM/EDS analysis reveals Si and Mg 
as constituting ions for talc (Fig. 5a) and Si, Al, Mg and very small amounts of Fe for chlinoclore (Fig. 5b). 
The phase recognition obtained by Raman spectroscopy is therefore confirmed by VP-SEM/EDS analysis. 
    Fig. 5.  
 
    (a) Energy spectrum registered under VP-SEM/EDS on the same Fibre as that shown in Fig. 3a showing 
Mg, Si and O as constituting ions, as expected for talc. (b) Energy spectrum registered under VP-SEM/EDS 
on the fibre in Fig. 4a and showing Mg, Si, Al, very small amounts of Fe and O as constituting ions, as 
expected for clinochlore. 
 
In addition to talc and chlinoclore crystals, many rounded formations measuring just a few microns in size 
were also observed in the pleural tissue (Fig. 6a and 6b). On the larger particles, which appear optically 
darker, the Raman spectrum reported in Fig. 7 was registered. The band wavenumbers allowed these 
particles to be ascribed to “hydroxyapatite” (HA), a phosphatic mineral with the chemical formula 
[Ca5(PO4)3(OH)] and typical of bone tissue. VP-SEM/EDS analysis performed on the same particles 
confirmed the presence of Ca, P, and O as the main constituting ions, as seen in Table 1. Many of the 
smaller rounded particles yielded the spectrum in Fig. 8a. This spectrum has only a few bands, the most 
intense of which appears at 972 cm−1, 10 cm−1 away from the most intense band in the HA spectrum. 
Three large humps lie near 1080, 560 and 405 cm−1. The band at 972 cm−1 appears asymmetric, so a 
fitting of this band was carried out. Two components were identified, with the first, more intense one at 
972 cm−1, and the other at 965 cm−1 (Fig. 8b). The bands in the Raman spectrum in Fig. 8a show 
wavenumbers detected on the Raman spectra from β-tricalcium phosphate (β-TCP), β-Ca3(PO4)2, a 
phase which crystallizes, depending on pH, Ca/P ratio and aging time, during the synthesis of the HA [34]. 
Nevertheless, data in the literature indicate that the spectra of β-TCP show two well-separated bands in 
the spectral region 980-950 cm−1: a more intense one near 970 cm−1 and another less intense near 946 
cm−1. A shoulder at 961 cm−1 is also reported [30], [31], [32], [33], [34], [35] and [36]. In our case, the 
band at 972 cm−1 always appeared intense, with a marked shoulder at 965 cm−1, whereas the band at 
946 cm−1 was never observed. For this reason, chemical quantitative microanalysis was carried out on 
the rounded crystallizations showing the Raman spectrum in Fig. 8a; the results from different particles 
are shown in Table 2. From the chemical data, Mg and Na appear replacing Ca in the crystal structure and 
a formula, calculated on the basis of 8 oxygens, (Ca2,71Mg0,25Na0,14)Σ3.1P1,99O8 may be proposed. 
Mg is reported to play a stabilizing role in the β-TCP structure by Dickens et al., 1974 [37], and Na has 
recently been reported by Quillard et al., 2011 [38] as replacing Ca in phosphates during the 
crystallization of Na and/or K substituted β-TCP. Moreover, considering that the Ca/P ratio expected for 
apatite is 1.67 and for β-TCMP ≤ 1.5 [31], on the basis of the SEM/EDS composition we may hypothesize 
crystallization of a phase close to β-TCMP [35]. However, in an experiment of mineralization in osteoblast 
cell cultures, and therefore in biological systems, Stewart et al. (2002) observed the crystallization of a 
phase showing on the Raman spectra only one large band at 975 cm−1; they assigned this phase to β-TCP 
[36]. 
    Fig. 6.  
 
    (a) Rounded particles observed by optical microscope in the pleura. (b) The same type of particles 
observed under Scanning Electron Microscopy (SEM), allowing determination of their size as a few 
microns. 
     Fig. 7.  
 
    Raman spectrum registered on a larger particle, like that shown in Fig. 6b, indicating hydroxyapatite, a 
calcium phosphate mineral; the circled bands are produced by the paraffin covering the histological 
section. 
 
    Table 1. 
 
Atomic % 
        
Analyses IN C O Si Mg Ca P Na S 
an01_in 89,84 6,01 0,61 0,17 1,66 1,32 0,40 0,00 
an02_in 88,74 6,75 0,65 0,00 1,92 1,50 0,45 0,00 
an03_in 89,50 5,70 0,74 0,16 1,99 1,51 0,40 0,00 
mean_IN 89,36 6,15 0,67 0,11 1,86 1,44 0,42 0,00 
Analyses OUT C O Si Mg Ca P Na S 
Atomic % 
        
Analyses IN C O Si Mg Ca P Na S 
an01_out 94,23 3,56 1,54 0,10 0,14 0,00 0,39 0,05 
an02_out 94,10 2,70 2,36 0,14 0,23 0,00 0,40 0,08 
mean_OUT 94,17 3,13 1,95 0,12 0,19 0,00 0,40 0,07 
MEAN'S DIFFERENCE -4,81 3,02 -1,28 -0,01 1,67 1,44 0,02 -0,07 
 
 
    VP-SEM/EDS analyses performed on a rounded crystal corresponding to 
hydroxyapatite on the basis of the Raman spectrum in Fig. 7. The values are expressed 
in atomic percent. The first three analyses were carried out on the particle (IN); the 
other two analyses in the area external, but close to it (OUT). Mean values of the 
three IN analyses and of the two OUT analyses were calculated and the difference 
represents the ions composing the analyzed particle: O, Ca and P, as expected for 
hydroxyapatite. 
 
    Fig. 8.  
 
    (a) Raman spectrum registered on smaller rounded particles, crystallization of a phase close to β-TCMP 
may be hypothesized. (b) Fitting of the most intense band at 972 cm−1 in the Raman spectrum reported 
in Fig. 8a. 
ANALYSES Ca Mg Na P Σ O (Ca + Mg + Na)/P 
An #01 2,69 0,25 0,15 2,00 5,08 8 1,54 
An #02 2,67 0,23 0,12 2,01 5,04 8 1,51 
An #03 2,67 0,24 0,17 2,00 5,08 8 1,54 
An #04 2,73 0,25 0,14 1,98 5,10 8 1,57 
An #05 2,78 0,26 0,10 1,96 5,11 8 1,61 
An #06 2,74 0,27 0,18 1,96 5,15 8 1,63 
Mean Values 2,71 0,25 0,14 1,99 5,09 8 
 
    Table 2. 
    Cations from quantitative SEM/EDS analyses performed on different rounded 
particles showing Raman spectrum in Fig. 8. The data were normalized to 8 O atoms. 
 
Phosphates were not detected in the powder used for pleurodesis by X-ray diffraction (Fig. 1) or under 
VP-SEM/EDS when the technique was applied on the starting talc used for pleurodesis to rule out a 
concentration of phosphate phases so low as to be undetectable by X-ray diffraction (<1%). The results 
described make it reasonable to hypothesize the crystallisation of these phosphate phases in the pleura 
of patients affected by MM. On the other hand, pulmonary calcifications and ossifications caused by 
different diseases are described by Chan et al. (2002) [39]; in the cases studied, it seems that the 
precipitation of β-TCMP and of HA occurs in the pleura. 
 
On the thin sections of lung tissue, near the talc-chlinoclore elongated crystals observed in the pleura, 
several “asbestos bodies”, like those represented in Fig. 9a and 9b, were identified in the lung. Micro-
Raman spectroscopy was applied on these corpuscles in an attempt to identify the mineral phase inside 
the coating material. Considering the “asbestos body” in Fig. 9b, when the laser beam was directed on 
the area indicated by the arrow in the figure, appearing less covered by the ferruginous coating material, 
the Raman spectrum shown in Fig. 10 was recorded. The wavenumbers of the Raman bands correspond 
to those most intense in the Raman spectra of the natural fibres of crocidolite, a mineral phase regulated 
as “asbestos” [25] and [40]. The same was obtained on other “asbestos bodies” in the thin sections 
examined. 
    Fig. 9.  
 
    (a and b) “Asbestos bodies” observed in the lung tissue. 
    Fig. 10.  
     Raman spectrum registered addressing the laser beam on the part of the “asbestos body” arrowed in 
Fig. 9b and almost free of coating material. All the Raman bands, except for the band at 892 cm−1 which 
also belongs to the paraffin film, are typical of crocidolite, which therefore proves to be the mineral 
phase of the incorporated fibre. 
 
4. Conclusions 
 
Micro-Raman spectroscopy is an effective technique for identifying the inorganic phases contained in 
thin sections of pleura and lung prepared for medical diagnosis of MM, allowing mineral phases used for 
pleurodesis to be distinguished from the other phases detected. Pleurodesis produces the proliferation of 
fibroblastic cells arranged haphazardly in fascicles around birefringent crystals, whose Raman spectra 
correspond to talc or clinochlore. In the present study, fibrous talc and clinochlore appear uncoated, and 
their Raman spectra indicate that the three-dimensional network of the crystalline structure is poorly 
affected by the mineral-cell interaction. Precipitation of a phase appearing very near that of β-TCMP, 
whose crystallization is observed in bone tissue when the Ca/P ratio is ≤ 1.50, and of apatite, which grows 
when the Ca/P ratio is higher [31] and [34], is observed in the pleura of the patients. Observation by OM 
of the alveolated lung parenchyma revealed ferruginous bodies, whose Raman spectra indicated the 
presence of crocidolite, an asbestos mineral in the core. Micro-Raman spectroscopy does not require 
sample preparation and can be applied directly to histological sections prepared for medical diagnosis; 
moreover, it also makes it possible to determine the position of the inorganic phases in the tissue and the 
reaction of the cellular medium around them. 
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